{"id":"sofosbuvir-daclatasvir","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, essential for viral replication. Daclatasvir is an NS5A inhibitor that disrupts viral protein complex formation and RNA replication. Together, this combination targets two critical steps in the HCV replication cycle, achieving high cure rates across multiple HCV genotypes.","oneSentence":"Sofosbuvir and daclatasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS5B polymerase and NS5A protein, respectively, blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:22.257Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotypes 1-6)"},{"name":"HCV in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT05992077","phase":"NA","title":"Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia","status":"ACTIVE_NOT_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-08-07","conditions":"HCV Infection","enrollment":21000},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT04943588","phase":"","title":"Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2021-11-01","conditions":"Hepatitis C, Chronic","enrollment":25000},{"nctId":"NCT06829966","phase":"","title":"Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-05-13","conditions":"Intestinal Microbiota Between Different Groups","enrollment":30},{"nctId":"NCT02262728","phase":"PHASE2","title":"An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-30","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT04468087","phase":"PHASE2, PHASE3","title":"Antiviral Agents Against COVID-19 Infection","status":"COMPLETED","sponsor":"Hospital do Coracao","startDate":"2021-02-15","conditions":"COVID-19","enrollment":256},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT03612973","phase":"NA","title":"Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Chronic Hepatitis c","enrollment":80},{"nctId":"NCT05854511","phase":"PHASE3","title":"Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-06-05","conditions":"HCV","enrollment":30},{"nctId":"NCT02596880","phase":"PHASE3","title":"Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-09","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT03540212","phase":"PHASE2, PHASE3","title":"Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-12-10","conditions":"Chronic HCV Infection","enrollment":50},{"nctId":"NCT05616598","phase":"PHASE2, PHASE3","title":"Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-03-01","conditions":"Male Infertility, HCV","enrollment":200},{"nctId":"NCT04852614","phase":"","title":"Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2020-12-01","conditions":"Hepatitis C Virus Infection","enrollment":10},{"nctId":"NCT03882307","phase":"EARLY_PHASE1","title":"Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-10","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT04561063","phase":"PHASE2","title":"COVID-19 Prophylaxis South Africa (COVER HCW)","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-12-08","conditions":"Covid19, SARS-CoV Infection","enrollment":1950},{"nctId":"NCT05372874","phase":"","title":"Treatment of Hepatitis c by Using Direct-acting Antiviral","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-05-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT03706898","phase":"PHASE1","title":"Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-10-01","conditions":"HIV-1-infection, Hepatic Impairment","enrollment":36},{"nctId":"NCT03158857","phase":"","title":"Hepatitis C Treatment Study in Myanmar","status":"WITHDRAWN","sponsor":"Myanmar Oxford Clinical Research Unit","startDate":"2022-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT05138523","phase":"","title":"Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)","status":"COMPLETED","sponsor":"Beker Laboratories","startDate":"2019-11-21","conditions":"Chronic Hepatitis c","enrollment":99},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT02640157","phase":"PHASE3","title":"A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Genotype 3 Hepatitis C Virus","enrollment":506},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT03480932","phase":"PHASE2, PHASE3","title":"Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-02-02","conditions":"Hepatitis C, Chronic","enrollment":150},{"nctId":"NCT03487848","phase":"PHASE2","title":"Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2018-06-25","conditions":"Hepatitis C, Chronic Hepatitis","enrollment":5},{"nctId":"NCT03883698","phase":"PHASE3","title":"Safety of Sofosbuvir in People With Advanced Kidney Failure","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2019-03-15","conditions":"Kidney Failure, Chronic, Hepatitis C","enrollment":30},{"nctId":"NCT04773756","phase":"PHASE4","title":"Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-11-01","conditions":"Covid19","enrollment":54},{"nctId":"NCT04535869","phase":"PHASE3","title":"Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2020-12-28","conditions":"COVID-19","enrollment":50},{"nctId":"NCT04113629","phase":"NA","title":"Simplified Monitoring Myanmar SM2 Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-01-22","conditions":"Hepatitis C, Liver Cirrhoses, Liver Inflammation","enrollment":200},{"nctId":"NCT03669835","phase":"NA","title":"The Sublimated Mare Milk Supplement in Hepatitis C","status":"COMPLETED","sponsor":"Asfendiyarov Kazakh National Medical University","startDate":"2018-03-28","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT04729153","phase":"","title":"Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-02","conditions":"Covid19","enrollment":100},{"nctId":"NCT04664894","phase":"","title":"Direct Acting Anti-Viral's In Chronic HCV Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2018-05-15","conditions":"Safety Issues","enrollment":511},{"nctId":"NCT04460443","phase":"PHASE2, PHASE3","title":"Sofosbuvir in Treatment of COVID 19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-08-01","conditions":"COVID","enrollment":60},{"nctId":"NCT04497649","phase":"PHASE2, PHASE3","title":"Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-07-01","conditions":"Covid19","enrollment":100},{"nctId":"NCT03283176","phase":"","title":"Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-03-01","conditions":"Liver Cirrhoses, Chronic Hepatitis c, Directly Acting Antivirals","enrollment":50},{"nctId":"NCT02175966","phase":"PHASE2","title":"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-07-28","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT04457050","phase":"PHASE4","title":"Effect of Hepatitis C Clearance on Insulin Resistance","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2017-10-30","conditions":"Insulin Resistance, Hepatitis C","enrollment":160},{"nctId":"NCT04443725","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-07","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04387526","phase":"PHASE2, PHASE3","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2016-04-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":946},{"nctId":"NCT04387539","phase":"PHASE1, PHASE2","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":94},{"nctId":"NCT03794258","phase":"PHASE2","title":"Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection","status":"WITHDRAWN","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-01","conditions":"HCV Infection","enrollment":""},{"nctId":"NCT04122066","phase":"","title":"the Pulmonary Safety of Antihepatitis C Treatment","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT04244383","phase":"PHASE4","title":"Expression of Inflammasomes in HCV Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-01","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03166943","phase":"NA","title":"the Possible Effect of the Antiviral Inhibitors for Treatment of Hepatitis C Virus Infection in Cardiac Function","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-05-10","conditions":"Hepatitis","enrollment":130},{"nctId":"NCT04211844","phase":"","title":"Metabolic Changes in Chronic HCV Patients Receiving DAAS","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-10-01","conditions":"Chronic Hepatitis C","enrollment":100},{"nctId":"NCT04159246","phase":"","title":"Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C","status":"UNKNOWN","sponsor":"Mohamed Saad","startDate":"2019-02-10","conditions":"HCV Infection","enrollment":30},{"nctId":"NCT03063879","phase":"PHASE4","title":"Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2017-04-01","conditions":"Hepatitis C, Chronic, Chronic Renal Failure","enrollment":95},{"nctId":"NCT03163849","phase":"PHASE3","title":"Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-09-01","conditions":"Chronic Hepatitis c","enrollment":50},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT03481036","phase":"NA","title":"DAA Therapy in Pediatric Patients With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":100},{"nctId":"NCT03488485","phase":"NA","title":"Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":50000},{"nctId":"NCT03965286","phase":"","title":"Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Antiviral Drug","enrollment":80},{"nctId":"NCT02304159","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics","status":"COMPLETED","sponsor":"Tarek I. Hassanein, M.D., FACP, FAG, AGAF","startDate":"2015-01","conditions":"Hepatitis C, Cirrhosis","enrollment":39},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03549832","phase":"NA","title":"Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-01-01","conditions":"HCV Coinfection","enrollment":40},{"nctId":"NCT03369327","phase":"PHASE3","title":"Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2017-01-01","conditions":"Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus","enrollment":232},{"nctId":"NCT03200184","phase":"PHASE4","title":"Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2016-09-01","conditions":"Hepatitis C","enrollment":1448},{"nctId":"NCT03547895","phase":"NA","title":"Management of Decompensated HCV Cirrhotic Patients","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2015-06-01","conditions":"Decompensated Cirrhosis","enrollment":80},{"nctId":"NCT03490097","phase":"PHASE2, PHASE3","title":"Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-12-01","conditions":"Chronic Hepatitis c, Metabolic Syndrome","enrollment":100},{"nctId":"NCT03665766","phase":"","title":"Effect of Cyclosporine A Versus Tacrolimus on Response to Antiviral Therapy After Hepatitis C Genotype -4 Recurrence Post Liver Transplantation","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-05-15","conditions":"Liver Transplantation","enrollment":126},{"nctId":"NCT03646396","phase":"NA","title":"Effect of Sofosbuvir-daclatasuvir on Angiogenesis","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2018-08-01","conditions":"HCV Coinfection","enrollment":40},{"nctId":"NCT03480269","phase":"","title":"Very Rapid and Rapid Virological Response as Predictors of Response of HCV Tretment","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-08-01","conditions":"Predictors of Response to HCV Tretment","enrollment":100},{"nctId":"NCT03572140","phase":"","title":"Safety of Sofosbuvir ,Daclatasvir in HCV Patients and RAVS in Resistent and Relapsed Cases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-07-01","conditions":"HCV","enrollment":297},{"nctId":"NCT03080415","phase":"PHASE3","title":"Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir","status":"COMPLETED","sponsor":"Yassin Abdelghaffar Charity Center for Liver Disease and Research","startDate":"2017-03-18","conditions":"Hepatitis C Genotype 4","enrollment":40},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT02673489","phase":"PHASE3","title":"A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-03-15","conditions":"Hepatitis C","enrollment":106},{"nctId":"NCT02576314","phase":"PHASE3","title":"Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05","conditions":"Chronic Hepatitis C Infection","enrollment":48},{"nctId":"NCT02482077","phase":"PHASE4","title":"Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":112},{"nctId":"NCT02473211","phase":"PHASE2, PHASE3","title":"SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":106},{"nctId":"NCT03186313","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection","status":"COMPLETED","sponsor":"Egyptian Liver Hospital","startDate":"2016-09","conditions":"Hepatitis C","enrollment":72},{"nctId":"NCT03169348","phase":"NA","title":"The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-11-01","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03318887","phase":"","title":"Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-02-01","conditions":"Hepatitis C","enrollment":130},{"nctId":"NCT02772744","phase":"","title":"Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2017-11-01","conditions":"Hepatitis C","enrollment":250},{"nctId":"NCT03296930","phase":"PHASE4","title":"Effect Of DAAs For Treatment Of HCV On Normal Kidney","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-10-01","conditions":"Antiviral Drug Adverse Reaction","enrollment":100},{"nctId":"NCT02628717","phase":"","title":"Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-07","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":558},{"nctId":"NCT03268317","phase":"","title":"Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-01","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT03247296","phase":"","title":"Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir","status":"UNKNOWN","sponsor":"MTI University","startDate":"2017-02-28","conditions":"Hepatitis C","enrollment":200},{"nctId":"NCT03241823","phase":"","title":"Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-12-01","conditions":"Hepatitis C, Liver Cirrhosis","enrollment":100},{"nctId":"NCT02624063","phase":"PHASE4","title":"Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2015-12","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT03226717","phase":"","title":"Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-08-10","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT03188276","phase":"EARLY_PHASE1","title":"The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-02-01","conditions":"Chronic Hepatitis C","enrollment":52},{"nctId":"NCT03166280","phase":"","title":"Hepatitis c and Vitamin D and Iron Status","status":"UNKNOWN","sponsor":"Eman Sayed Hassan Abd Allah","startDate":"2017-06","conditions":"Hepatitis C","enrollment":87},{"nctId":"NCT02932293","phase":"PHASE2","title":"Triple Combination DAAs for Treating HCV GT1b Subjects","status":"WITHDRAWN","sponsor":"Humanity and Health Research Centre","startDate":"2016-12","conditions":"Chronic Hepatitis C Infection","enrollment":""},{"nctId":"NCT03149289","phase":"","title":"Hepatitis C Virus Infection in Patients With Hemoglobinopathies","status":"COMPLETED","sponsor":"Società Italiana Talassemie ed Emoglobinopatie","startDate":"2015-03-01","conditions":"Hepatitis C, Chronic, Hemoglobinopathies","enrollment":168},{"nctId":"NCT03133065","phase":"PHASE4","title":"Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-09","conditions":"Liver Transplantation","enrollment":89},{"nctId":"NCT02349048","phase":"PHASE2","title":"Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-01","conditions":"Hepatitis C Virus","enrollment":68},{"nctId":"NCT03063723","phase":"","title":"Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-01-01","conditions":"Chronic Hepatitis C (Disorder)","enrollment":25},{"nctId":"NCT02657694","phase":"","title":"Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods","status":"UNKNOWN","sponsor":"FixHepC","startDate":"2015-07-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT02032875","phase":"PHASE3","title":"Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-03","conditions":"Hepatitis C","enrollment":116},{"nctId":"NCT02319031","phase":"PHASE3","title":"Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-02","conditions":"Hepatitis C","enrollment":53},{"nctId":"NCT02057003","phase":"","title":"Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients","status":"UNKNOWN","sponsor":"Valme University Hospital","startDate":"2012-01","conditions":"Hepatitis C, Chronic, Human Immunodeficiency Virus","enrollment":1000},{"nctId":"NCT02771405","phase":"PHASE3","title":"Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC","status":"UNKNOWN","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2016-03","conditions":"Hepatitis C, Chronic, Hepatocellular Carcinoma","enrollment":150},{"nctId":"NCT02531269","phase":"","title":"Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-03","conditions":"Hepatitis C","enrollment":249},{"nctId":"NCT02470858","phase":"PHASE2","title":"Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":18},{"nctId":"NCT02161939","phase":"","title":"A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C","status":"NO_LONGER_AVAILABLE","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT02097966","phase":"","title":"EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C","status":"NO_LONGER_AVAILABLE","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"Chronic Hepatitis C","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"HEPATITIS B REACTIVATION"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"CROHN^S DISEASE"},{"count":1,"reaction":"ILEAL ULCER"},{"count":1,"reaction":"SALMONELLOSIS"},{"count":1,"reaction":"SPONTANEOUS BACTERIAL PERITONITIS"}],"_approvalHistory":[],"publicationCount":229,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sofosbuvir + Daclatasvir","genericName":"Sofosbuvir + Daclatasvir","companyName":"Egyptian Liver Hospital","companyId":"egyptian-liver-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofosbuvir and daclatasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS5B polymerase and NS5A protein, respectively, blocking viral replication. Used for Chronic hepatitis C virus infection (genotypes 1-6), HCV in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}